Alessandra Gennari

Summary

Affiliation: National Cancer Research Institute
Country: Italy

Publications

  1. ncbi Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Alessandra Gennari
    National Cancer Research Institute, Genoa, Italy
    Breast Cancer Res Treat 115:131-6. 2009
  2. ncbi New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations
    Alessandra Gennari
    National Cancer Research Institute, Genoa, Italy
    Clin Breast Cancer 8:S179-83. 2008
  3. ncbi Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, Genoa, Italy
    J Clin Oncol 24:3912-8. 2006
  4. ncbi HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    J Natl Cancer Inst 100:14-20. 2008
  5. ncbi Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials
    Alessandra Gennari
    Galliera Hospital, Genoa, Italy
    J Clin Oncol 29:2144-9. 2011
  6. ncbi Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial
    Bernardo Bonanni
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, Genoa, Italy
    J Clin Oncol 30:2593-600. 2012
  7. ncbi Exemestane for breast cancer prevention: a critical shift?
    Andrea Decensi
    Division of Medical Oncology, Office of the Scientific Director, E O Ospedali Galliera, Genoa, Italy
    Cancer Discov 2:25-40. 2012
  8. ncbi A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
    Carlotta Defferrari
    Unit of Medical Oncology, E, O, Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    J Ovarian Res 5:17. 2012
  9. ncbi Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer
    Alessandra Gennari
    Division of Medical Oncology, Galliera Hospital, Via Volta n 6, 16125, Genoa, Italy
    Curr Oncol Rep 14:20-6. 2012
  10. ncbi Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies
    Alessandra Gennari
    Department of Oncology, Division of Medical Oncology, Santa Chiara University Hospital, Pisa, Italy
    Cancer 104:1742-50. 2005

Detail Information

Publications14

  1. ncbi Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Alessandra Gennari
    National Cancer Research Institute, Genoa, Italy
    Breast Cancer Res Treat 115:131-6. 2009
    ..This phase II study, evaluated the activity and cardiotoxicity of first-line epirubicin plus low-dose trastuzumab (LD-T) in patients with HER2 positive MBC...
  2. ncbi New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations
    Alessandra Gennari
    National Cancer Research Institute, Genoa, Italy
    Clin Breast Cancer 8:S179-83. 2008
    ....
  3. ncbi Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, Genoa, Italy
    J Clin Oncol 24:3912-8. 2006
    ..This randomized study compared maintenance paclitaxel with control in metastatic breast cancer patients not experiencing progression after first-line anthracycline/paclitaxel combination chemotherapy...
  4. ncbi HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials
    Alessandra Gennari
    National Cancer Research Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy
    J Natl Cancer Inst 100:14-20. 2008
    ..We performed a pooled analysis of the interaction between HER2 status and the efficacy of adjuvant anthracyclines based on the published subset data...
  5. ncbi Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials
    Alessandra Gennari
    Galliera Hospital, Genoa, Italy
    J Clin Oncol 29:2144-9. 2011
    ..To evaluate the effect of different first-line chemotherapy durations in patients with metastatic breast cancer (MBC) on overall survival (OS) and progression-free survival (PFS)...
  6. ncbi Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial
    Bernardo Bonanni
    Division of Medical Oncology, E O Ospedali Galliera, Mura delle Cappuccine 14, Genoa, Italy
    J Clin Oncol 30:2593-600. 2012
    ..The change in Ki-67 between pretreatment biopsy and post-treatment surgical specimen has prognostic value and may predict antitumor activity in breast cancer...
  7. ncbi Exemestane for breast cancer prevention: a critical shift?
    Andrea Decensi
    Division of Medical Oncology, Office of the Scientific Director, E O Ospedali Galliera, Genoa, Italy
    Cancer Discov 2:25-40. 2012
    ..In addition to describing key findings from the publication of MAP.3 and related trials, our review undertakes a detailed analysis of the strengths and weaknesses of MAP.3 as well as the implications for future prevention research...
  8. ncbi A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
    Carlotta Defferrari
    Unit of Medical Oncology, E, O, Ospedali Galliera, Mura delle Cappuccine 14, 16128, Genoa, Italy
    J Ovarian Res 5:17. 2012
    ..abstract:..
  9. ncbi Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer
    Alessandra Gennari
    Division of Medical Oncology, Galliera Hospital, Via Volta n 6, 16125, Genoa, Italy
    Curr Oncol Rep 14:20-6. 2012
    ..In this paper, we summarize the current and future applications of PET in the management of breast cancer...
  10. ncbi Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies
    Alessandra Gennari
    Department of Oncology, Division of Medical Oncology, Santa Chiara University Hospital, Pisa, Italy
    Cancer 104:1742-50. 2005
    ..The aim of this study was to evaluate the impact of new agents on prognosis of MBC patients enrolled in clinical trials of first-line chemotherapy...
  11. ncbi Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer
    Alessandra Gennari
    Division of Medical Oncology, Department of Oncology, University Hospital Santa Chiara, Pisa, Italy
    Clin Breast Cancer 3:346-52. 2002
    ..This regimen represents a valid option as a salvage treatment in taxane- and anthracycline-pretreated patients...
  12. ncbi Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma 55, Italy
    Br J Clin Pharmacol 53:508-18. 2002
    ..To investigate the pharmacokinetics and pharmacodynamics of epirubicin and paclitaxel in combination, as well as the effects of paclitaxel and its vehicle Cremophor EL on epirubicin metabolism...
  13. ncbi Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Clin Pharmacokinet 41:431-44. 2002
    ....
  14. ncbi Pemetrexed: a promising new treatment for breast cancer
    Alessandra Gennari
    Baylor-Sammons Cancer Center, US Oncology, Dallas, TX, USA
    Semin Oncol 29:36-41. 2002
    ....